Product Description
Peficitinib [Smyraf (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis.
Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor,TYK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Arthritis, Rheumatoid
Phase 2: Arthritis, Rheumatoid|Inflammation|Colitis, Ulcerative|Psoriasis
Phase 1: Healthy Volunteers|Other|Arthritis, Rheumatoid|Psoriasis|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 015K-MA-3311 | N/A |
Recruiting |
Arthritis, Rheumatoid |
2025-12-31 |
|
| CTR20181199 | P3 |
Completed |
Arthritis, Rheumatoid |
2021-10-27 |
|
| 015K-CL-CNA3 | P3 |
Completed |
Arthritis, Rheumatoid |
2021-04-01 |
|
| 015K-CL-CNA1 | P1 |
Completed |
Healthy Volunteers |
2020-12-21 |